A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Beninato Teresa
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: BNT327
Pathologies: Lung cancer
A Phase II/III, multisite, randomized master protocol trial on the efficacy, tolerability, and safety of BNT327 in combination with chemotherapy compared to pembrolizumab plus chemotherapy in patients with first-line non-small cell lung cancer (NSCLC). The trial is divided into two parts:
Phase II Part: A randomized trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of two different dose levels of BNT327 (20 mg/kg versus 30 mg/kg every 3 weeks) in combination with chemotherapy.
Phase III Part: A global, randomized trial to compare the efficacy and safety of BNT327 in combination with chemotherapy (Experimental Arm) versus pembrolizumab plus chemotherapy (Standard of Care Control Arm), with enrollment expanded to 1220 participants.
Last update: 13/07/2026